Results 111 to 120 of about 51,741 (305)

Acute hepatitis following mRNA BNT162b2 COVID-19 vaccination

Canadian Liver Journal, 2022
BACKGROUND: Widespread administration of COVID-19 vaccinations have led to reports of rare but potentially serious side effects. METHODS: We present two cases of acute hepatitis following mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccination. RESULTS: A 25-year-old male presented to hospital with progressive jaundice 5 days following his second dose ...
Matthew, Cheah, Safwat, Girgis, Vincent G, Bain   +2 more
openaire   +2 more sources

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

MMWR. Morbidity and mortality weekly report, 2021
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines ...
M. Thompson, J. Burgess, A. Naleway, Harmony L. Tyner, Sarang K. Yoon, J. Meece, Lauren E. W. Olsho, A. Caban-Martinez, A. Fowlkes, K. Lutrick, J. Kuntz, K. Dunnigan, M. Odean, K. Hegmann, Elisha L Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, L. Grant, K. Ellingson, H. Groom, Tnelda Zunie, M. Thiese, L. Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, J. Gerald, Rachel T. Brown, Meghan K Herring, G. Joseph, S. Beitel, Tyson Morrill, Josephine Mak, P. Rivers, K. Harris, D. Hunt, Melissa L. Arvay, P. Kutty, A. Fry, M. Gaglani   +43 more
semanticscholar   +1 more source

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

BMC Rheumatology, 2023
Background The importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality.
Fulya Cosan, Ozlem Unay Demirel, Demet Yalcin, Muhammed Mert Sonkaya, Isilsu Ezgi Uluisik, Olida Cecen, Yavuz Furuncuoglu, Deniz Maktav Celikmen, Osman Kara, Erkan Ceylan, Timucin Avsar   +10 more
doaj   +1 more source

Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy

Vaccines, 2022
In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines were compared 6 months after the two-dose immunization of healthy individuals.
Zsolt Matula, Márton Gönczi, Gabriella Bekő, Béla Kádár, Éva Ajzner, Ferenc Uher, István Vályi-Nagy   +6 more
doaj   +1 more source

Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers

International Journal of Infectious Diseases, 2022
Objectives: There are limited comparative immunologic durability data post COVID-19 vaccinations. Methods: Approximately 8.4 months after primary COVID-19 vaccination, 647 healthcare workers completed surveys about COVID-19 vaccinations/infections and ...
Wendy M. Brunner, Daniel Freilich, Jennifer Victory, Nicole Krupa, Melissa B. Scribani, Paul Jenkins, Emily G. Lasher, Amanda Fink, Anshini Shah, Peggy Cross, Valerie Bush, Laura J. Peek, Gary A. Pestano, Anne M. Gadomski   +13 more
doaj   +1 more source

Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines-an exploratory sub-study of the BRACE trial [PDF]

Background: The COVID-19 pandemic led to the rapid development and deployment of several highly effective vaccines against SARS-CoV-2. Recent studies suggest that these vaccines may also have off-target effects on the immune system.
Arnaiz de las Revillas Almajano, Francisco, Bonnici, Rhian, Curtis, Nigel C., Davidson, Andrew, Fariñas Álvarez, María del Carmen, Gardiner, Kaya, Germano, Susie, Grubor Bauk, Branka, Gutiérrez Cuadra, Manuel, Gwee, Amanda, Kanta Subbarao, Lynn, David J., McDonald, Ellie A., McElroy, Rebecca, Messina, Nicole L., Nicholson, Suellen R., Perrett, Kirsten P., Pittet, Laure F., Rudraraju, Rajeev, Stevens, Natalie E.   +19 more
core   +1 more source

Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination

medRxiv, 2021
Background: The SARS-CoV-2 pandemic has led to the development of various vaccines. Real-life data on immune responses elicited in the most vulnerable group of vaccinees over 80 years old is still underrepresented despite the prioritization of the ...
L. Müller, M. Andrée, Wiebke Moskorz, I. Drexler, Lara Walotka, Ramona Grothmann, Johannes Ptok, J. Hillebrandt, Anastasia Ritchie, Denise Rabl, P. Ostermann, Rebekka Robitzsch, S. Hauka, A. Walker, Christopher Menne, Ralf Grutza, J. Timm, O. Adams, H. Schaal   +18 more
semanticscholar   +1 more source

Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations

Vaccines, 2023
To compare immunogenicity and reactogenicity of five COVID-19 vaccine regimens against wild-type SARS-CoV-2 and variants of concern (VoCs) among Thai populations, a prospective cohort study was conducted among healthy participants aged ≥18 years who had ...
Tavitiya Sudjaritruk, Oramai Mueangmo, Jutamad Saheng, Poramed Winichakoon, Parichat Salee, Worawan Wongjak, Tanachot Chaito, Jutarat Praparattanapan, Khanuengnit Nuket, Nuttarika Solai, Jiraprapa Wipasa, Kriangkrai Chawansuntati, Romanee Chaiwarith   +12 more
doaj   +1 more source

Systematic review of the oral manifestations produced by the SARS-CoV-2 vaccine [PDF]

, 2023
To combat the coronavirus pandemic different vaccines have been developed. However, diverse adverse effects have been reported due to their use, including oral manifestations.
Leco Berrocal, María Isabel, López Carriches, Carmen, Santana-Torres, Tomás, Taheri, Ricardo Bahram   +3 more
core   +1 more source

Potent and Long‐Lasting Immunogenicity Generated by LNP‐mRNA gE Antigen Against Varicella Zoster Virus via an AI‐Assisted Pipeline

Advanced Science, EarlyView.
This study designs a novel mRNA‐LNP vaccine targeting VZV glycoprotein E (gE) for herpes zoster via an AI‐assisted pipeline. Validated in mice and rhesus macaques, the mRNA‐LNP vaccine shows strong humoral and cellular immune responses, with CD4+ T‐cell responses more effective and durable than Shingrix, offering a promising prophylactic option ...
Kai Dong, Fang Liu, Dawei Wang, Yanfen Li, Man Zhang, Yuting Zhou, Gengshen Song   +6 more
wiley   +1 more source